157 related articles for article (PubMed ID: 11200205)
1. The role of positron emission tomography in skeletal disease.
Cook GJ; Fogelman I
Semin Nucl Med; 2001 Jan; 31(1):50-61. PubMed ID: 11200205
[TBL] [Abstract][Full Text] [Related]
2. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography.
Cook GJ; Fogelman I
Q J Nucl Med; 2001 Mar; 45(1):47-52. PubMed ID: 11456375
[TBL] [Abstract][Full Text] [Related]
3. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography.
Even-Sapir E; Mishani E; Flusser G; Metser U
Semin Nucl Med; 2007 Nov; 37(6):462-9. PubMed ID: 17920353
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Flusser G; Zuriel L; Kollender Y; Lerman H; Lievshitz G; Ron I; Mishani E
J Nucl Med; 2004 Feb; 45(2):272-8. PubMed ID: 14960647
[TBL] [Abstract][Full Text] [Related]
6. The role of positron emission tomography in the management of bone metastases.
Cook GJ; Fogelman I
Cancer; 2000 Jun; 88(12 Suppl):2927-33. PubMed ID: 10898336
[TBL] [Abstract][Full Text] [Related]
7. [Positron-emission tomography of the skeletal system using 18FNa: the incidence, pattern of the findings and distribution of benign changes].
Schirrmeister H; Kotzerke J; Rentschler M; Träger H; Fenchel S; Nüssle K; Diederichs CG; Reske SN
Rofo; 1998 Sep; 169(3):310-4. PubMed ID: 9779073
[TBL] [Abstract][Full Text] [Related]
8. Whole body skeletal imaging with [18F]fluoride ion and PET.
Hoh CK; Hawkins RA; Dahlbom M; Glaspy JA; Seeger LL; Choi Y; Schiepers CW; Huang SC; Satyamurthy N; Barrio JR
J Comput Assist Tomogr; 1993; 17(1):34-41. PubMed ID: 8419436
[TBL] [Abstract][Full Text] [Related]
9. Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT.
Petrén-Mallmin M; Andréasson I; Ljunggren O; Ahlström H; Bergh J; Antoni G; Långström B; Bergström M
Skeletal Radiol; 1998 Feb; 27(2):72-6. PubMed ID: 9526771
[TBL] [Abstract][Full Text] [Related]
10. Unsuspected skeletal sarcoidosis mimicking metastatic disease on FDG positron emission tomography and bone scintigraphy.
Ludwig V; Fordice S; Lamar R; Martin WH; Delbeke D
Clin Nucl Med; 2003 Mar; 28(3):176-9. PubMed ID: 12592122
[TBL] [Abstract][Full Text] [Related]
11. [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT].
Moragas M; Soler M; Riera E; García JR
Rev Esp Med Nucl Imagen Mol; 2015; 34(1):45-8. PubMed ID: 24690280
[TBL] [Abstract][Full Text] [Related]
12. Skeletal PET with 18F-fluoride: applying new technology to an old tracer.
Grant FD; Fahey FH; Packard AB; Davis RT; Alavi A; Treves ST
J Nucl Med; 2008 Jan; 49(1):68-78. PubMed ID: 18077529
[TBL] [Abstract][Full Text] [Related]
13. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
[TBL] [Abstract][Full Text] [Related]
14. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
15. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.
Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G
Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210
[TBL] [Abstract][Full Text] [Related]
16. 18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound.
Avery R; Kuo PH
Clin Nucl Med; 2013 Sep; 38(9):746-8. PubMed ID: 23797230
[TBL] [Abstract][Full Text] [Related]
17. Bone metastases radiopharmaceuticals: an overview.
Cuccurullo V; Cascini GL; Tamburrini O; Rotondo A; Mansi L
Curr Radiopharm; 2013 Mar; 6(1):41-7. PubMed ID: 23470032
[TBL] [Abstract][Full Text] [Related]
18. FDG PET in the clinical evaluation of sarcoidosis with bone lesions.
Kobayashi A; Shinozaki T; Shinjyo Y; Kato K; Oriuchi N; Watanabe H; Takagishi K
Ann Nucl Med; 2000 Aug; 14(4):311-3. PubMed ID: 11023033
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET.
Hawkins RA; Choi Y; Huang SC; Hoh CK; Dahlbom M; Schiepers C; Satyamurthy N; Barrio JR; Phelps ME
J Nucl Med; 1992 May; 33(5):633-42. PubMed ID: 1569473
[TBL] [Abstract][Full Text] [Related]
20. Detection of occult bone metastases of lung cancer with fluorine-18 fluorodeoxyglucose positron emission tomography.
Foo SS; Ramdave S; Berlangieri SU; Scott AM
Australas Radiol; 2004 Jun; 48(2):214-6. PubMed ID: 15230758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
